| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 30, 2026 |
| Accession Number: | 0001213900-26-034076 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Company completed treatment in four additional participate at its Israel clinical site Vancouver, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment and follow-up of 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disord
Vancouver, Canada, March 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application in India covering innovative next-generation psychedelic-based compounds for the treatment of mental health disorders and addiction. The patent application, filed with the Indian Patent Office, forms part of the Company's expanding global intellectual property portfolio and builds upon its exclusive worldwide licens
Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful continuation of treatment of participants in the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This positive progress follows the Company's recent announcement on March
EFFECT - Clearmind Medicine Inc. (0001892500) (Filer)
EFFECT - Clearmind Medicine Inc. (0001892500) (Filer)
6-K - Clearmind Medicine Inc. (0001892500) (Filer)
Vancouver, Canada, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable Hadassah Medical Center, a leading clinical site in Israel, to join the Company's clinical trial, of which the fir
Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind's US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines. Prior to joining Cl
Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial Tel Aviv, Israel / Vancouver, Canada, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. is pleased to announce that the company has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine, to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder (AUD). The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD su
SC 13G/A - Clearmind Medicine Inc. (0001892500) (Subject)